• Empathy Plant Co. has recently submitted the first production order for its Complete Plant Protein product line
  • All Empathy Plant Co. offerings will showcase 100% compostable packaging
  • Empathy Plant Co. has also finalized the formulation for a new product offering called Green Energy Powder
  • Canbud Distribution Corporation is a science and technology health and wellness company
  • Canbud (CBDX) opened trading at C$0.215 per share

Canbud’s (CBDX) subsidiary Empathy Plant Co. has recently submitted the first production order for its Complete Plant Protein product line.

Complete Plant Protein is a plant-based blend of pea and hemp protein.

To further position the brand in the market, all Empathy Plant Co. offerings will showcase 100% compostable packaging, a first in the plant-based market.

Additionally, Empathy Plant Co. has finalized the formulation for a new product offering called Green Energy Powder. This innovative product provides an industry-first converging a greens superfood complex with natural caffeine sources, aimed to support the needs and preferences of the brand’s 18-24-year-old female target market.

Canbud’s CEO, Steve Singh commented,

“The Empathy Plant Co. team is executing in a very timely and methodical manner and market conditions are primed for the new innovations and offerings. These developments push us closer to meaningful commercialization.”

The time of market release will be announced at a further date once production timelines are finalized.

Canbud Distribution Corporation is a science and technology health and wellness company that encompasses plant-based, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) verticals.

Canbud (CBDX) opened trading at C$0.215 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.